Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy

In patients with treatment‐resistant epilepsy (TRE), cannabidiol (CBD) produces variable improvement in seizure control. Patients in the University of Alabama at Birmingham CBD Expanded Access Program (EAP) were enrolled in the genomic study and genotyped using the Affymetrix Drug Metabolizing Enzym...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2021-11, Vol.110 (5), p.1368-1380
Hauptverfasser:	Davis, Brittney H., Beasley, T. Mark, Amaral, Michelle, Szaflarski, Jerzy P., Gaston, Tyler, Perry Grayson, Leslie, Standaert, David G, Bebin, E. Martina, Limdi, Nita A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Anticonvulsants - adverse effects Anticonvulsants - therapeutic use Cannabidiol - adverse effects Cannabidiol - therapeutic use Child Child, Preschool Compassionate Use Trials - methods Diarrhea - chemically induced Drug Resistant Epilepsy - diagnosis Drug Resistant Epilepsy - drug therapy Drug Resistant Epilepsy - genetics Female Forecasting Gene Regulatory Networks - drug effects Gene Regulatory Networks - genetics Genetic Variation - drug effects Genetic Variation - genetics Humans Male Pharmacogenetics - methods Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!